← Back to Search

Telehealth Support for Young Cancer Patients

N/A

Recruiting

Research Sponsored by University of California, Davis

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be younger than 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up end of the study period (6 cycles of chemotherapy for each participant, where each cycle is 14-28 days)

Awards & highlights

Study Summary

This trial will test how well a new telehealth system works to help improve communication between young cancer patients and their medical providers during chemotherapy treatment.

Who is the study for?

This trial is for young cancer patients who are currently undergoing treatment and have completed at least two chemotherapy cycles. They must be able to use Epic MyChart, which the study can help set up, and need a smartphone or tablet for telehealth appointments. It's not open to those who don't speak English or Spanish, may finish therapy during the study, or plan to leave UCDCCC.Check my eligibility

What is being tested?

The trial is examining how well a telehealth intervention works in helping adolescent and young adult cancer patients communicate with their healthcare providers while they're receiving chemotherapy treatments.See study design

What are the potential side effects?

Since this trial focuses on communication via telehealth rather than new medications, there aren't direct side effects like you'd expect from drug trials. However, participants might experience technical issues or privacy concerns.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ end of the study period (6 cycles of chemotherapy for each participant, where each cycle is 14-28 days)

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~end of the study period (6 cycles of chemotherapy for each participant, where each cycle is 14-28 days)

This trial's timeline: 3 weeks for screening, Varies for treatment, and end of the study period (6 cycles of chemotherapy for each participant, where each cycle is 14-28 days) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Proportion of Patients Completing the Trial

Secondary outcome measures

Survey Response Rate

Telemedicine Satisfaction and Usefulness Questionnaire (TSUQ)

Trial Design

2Treatment groups

Experimental Treatment

Group I: Immediate Intervention ArmExperimental Treatment2 Interventions

Observation periods will be from 4 days post last administration of chemotherapy until the next chemotherapy administration. All patients will undergo an initial observation period that will span two chemotherapy cycles and will be receiving clinical care as usual determined by the primary oncology team. Patients enrolled on the immediate arm will start the intervention (telehealth visits) in Time Period 2 (following chemotherapy cycles 3 and 4). During Time Period 3 (following chemotherapy cycles 5 and 6), this arm will resume clinical care as usual.

Group II: Delayed Intervention ArmExperimental Treatment2 Interventions

Observation periods will be from 4 days post last administration of chemotherapy until the next chemotherapy administration. All patients will undergo an initial observation period that will span two chemotherapy cycles and will be receiving clinical care as usual determined by the primary oncology team. Patients enrolled on the delayed arm will receive clinical care as usual during Time Period 2 (following chemotherapy cycles 3 and 4). During Time Period 3 (following chemotherapy cycles 5 and 6), this arm will start the intervention (telehealth visits).

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Standard of Care

2017

Completed Phase 4

~4420

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

University of California, DavisLead Sponsor

910 Previous Clinical Trials

4,706,971 Total Patients Enrolled

Media Library

Standard of Care Clinical Trial Eligibility Overview. Trial Name: NCT04594096 — N/A

Cancer Research Study Groups: Delayed Intervention Arm, Immediate Intervention Arm

Cancer Clinical Trial 2023: Standard of Care Highlights & Side Effects. Trial Name: NCT04594096 — N/A

Standard of Care 2023 Treatment Timeline for Medical Study. Trial Name: NCT04594096 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this research study open to participants under the age of twenty?

"The parameters for this medical study require the participants to be between 12-29 years old. There are 61 investigations into those younger than 18, and 432 studies involving individuals over 65."

Answered by AI

What patient criteria must be met to participate in this medical study?

"This medical trial requires 20 young adults, aged 12 to 29 years old with a malignancy. Furthermore, they must have received two cycles of chemotherapy prior to enrollment and possess access Epic MyChart or technology (smartphone/tablet) to participate in telehealth appointments."

Answered by AI

How many participants have enrolled in the research project thus far?

"Affirmative. Clinicaltrials.gov contains information that signifies this study is presently enrolling participants, having been first posted on September 30th 2021 and last edited on August 28th 2022. The trial requires 20 patients to be enrolled from 2 different sites."

Answered by AI

Is this experiment accepting volunteers at present?

"Affirmative. Online records on clinicaltrials.gov inform us that this medical investigation, which was initially posted on September 30th 2021, is still recruiting participants. The study needs to enlist 20 patients from 2 different sites."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Improving Treatment-Related Symptom Management in Adolescents and Young Adults With Cancer

2021. "Improving Treatment-Related Symptom Management in Adolescents and Young Adults With Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04594096.